• CME - 1.50
• NCPD - 1.50
• CPE - 1.50
• 1.50 - AAPA Category 1 CME

Price:

• Live Event: Free for HFSA Members and Non-Members
• OnDemand: Free for HFSA Members / $59 Non-Members

Program Overview
This new HFSA offering will focus on the role of devices in heart failure. This 90-minute webinar will include four didactic lectures with panel Q&A to be held after each lecture. Topics include the current state of devices in HF, how to start a device program and implement device strategies into clinical management, how to set-up a remote monitoring clinic, and novel devices entering testing and trials.

Learning Objectives
Following this activity, participants will be able to:

1. Recognize the lack of uniform guidelines and the need for standardized cardiac monitoring in cancer therapies beyond anthracyclines and trastuzumab.
2. Explain the evolving concept of permissive cardiotoxicity and how it may allow continued cancer treatment while managing cardiac risk in high-risk patients.
3. Identify urgent treatment steps for ICI-associated myocarditis and explore therapies beyond corticosteroids.
4. Discuss heart transplant eligibility in cancer patients, emphasizing a personalized approach.

• Michelle BLoom, MD
• Ana Barac, MD, PhD

• Richard K. Cheng, MD, MSc
• Anju Nohria, MD, MSc
• Alana Ferrari, PharmD, BCOP
• Anita Deswal, MD, MPH
• Nicolas Palaskas, MD
• Daniel Lenihan, MD
• Anne Blaes, MD
• Kerry Skurka, RN, BSN, MS